STOCKWATCH
·
Pharmaceuticals
Quarterly Result25 Jul 2025, 01:36 pm

Cipla Q1 FY26 Results: Profitability Momentum Continues with Strong EBITDA Margin at 25.6%

AI Summary

Cipla Limited announced its unaudited consolidated financial results for the quarter ended June 30th, 2025. The company's One-India business delivered a growth of 6% YoY, breaching the threshold of INR 3,000 Cr for the first time ever in the opening quarter of any financial year. North America business delivered a quarterly revenue of $226 Mn, driven by the performance of differentiated assets. One Africa recorded a strong growth of 11% YoY in USD terms. Emerging Markets and Europe delivered a healthy revenue growth of 8% YoY in USD terms. R&D investments stood at INR 432 Cr or 6.2% of sales.

Key Highlights

  • One-India business delivered a growth of 6% YoY
  • North America business delivered a quarterly revenue of $226 Mn
  • One Africa recorded a strong growth of 11% YoY in USD terms
  • Emerging Markets and Europe delivered a healthy revenue growth of 8% YoY in USD terms
  • R&D investments stood at INR 432 Cr or 6.2% of sales
CIPLA
Pharmaceuticals
CIPLA LTD.

Price Impact